ReviewCurrent neuropharmacology2019
Alzheimer's Disease - Future Therapy Based on Dendrimers.
Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 64 citations in OpenAlex.
- Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease.Drug delivery · 2026Review
- Alzheimer's Disease and Polymeric Nanocarriers: Synergistic Advances in Targeted Drug Delivery.Current topics in medicinal chemistry · 2025Review
- Dendrimers-Novel Therapeutic Approaches for Alzheimer's Disease.Biomedicines · 2024Review
- Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer's Disease.Molecular neurobiology · 2024Review
- Lipidic Nanoparticles, Extracellular Vesicles and Hybrid Platforms as Advanced Medicinal Products: Future Therapeutic Prospects for Neurodegenerative Diseases.Pharmaceutics · 2024Review
- Biomaterials-based anti-inflammatory treatment strategies for Alzheimer's disease.Neural regeneration research · 2024Review
- Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development.Cellular and molecular neurobiology · 2023Review
- Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review.IET nanobiotechnology · 2023Review
- Dendrimers in Alzheimer's Disease: Recent Approaches in Multi-Targeting Strategies.Pharmaceutics · 2023Review
- Data-driven causal model discovery and personalized prediction in Alzheimer's disease.NPJ digital medicine · 2022Article
- Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.Molecules (Basel, Switzerland) · 2022Review
- Dendrimers as Antiamyloid Agents.Pharmaceutics · 2022Review
- The application of nanotechnology in treatment of Alzheimer's disease.Frontiers in bioengineering and biotechnology · 2022Review
- Nasal delivery of neurotherapeuticsFrontiers in pharmacology · 2022Review
- Cationic Carbosilane Dendrimers Prevent Abnormal α-Synuclein Accumulation in Parkinson's Disease Patient-Specific Dopamine Neurons.Biomacromolecules · 2021Article
- Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.Molecules (Basel, Switzerland) · 2021Review
- Health Science Community Will Miss This Bright and Uniting Star: In Memory of Professor Gjumrakch Aliev, M.D, Ph.D.Cancers · 2021Article
- Nanomedicine: A Promising Way to Manage Alzheimer's Disease.Frontiers in bioengineering and biotechnology · 2021Review
- Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease.Frontiers in synaptic neuroscience · 2020Review
- Role of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer's Disease.Current neuropharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is characterized by the loss of neurons. It is the most common cause of dementia in the elderly population accompanied by pathological degeneration of neurofibrillary tangles. Senile plaques are formed with beta-amyloid, hyperphosphoryled tau protein, apolipoprotein E and presenilin associated with protease activity [amyloid beta (Aβ), gamma-secretase (γS)]. The molecular mechanisms of neurodegeneration include apoptosis, oxidative stress (free radical generation), inflammation, immune activation, and others. The lack of effective treatments for AD stems mainly from the incomplete understanding the causes of AD. Currently, there are several hypotheses explaining the early mechanisms of AD pathogenesis. Recent years witnessed an unprecedented research growth in the area of nanotechnology, which uses atomic, molecular and macromolecular methods to create products in microscale (nanoscale) dimensions. In this article, we have discussed the role of nanotechnology in the development and improvement of techniques for early diagnosis and effective treatment of AD. Since AD pathology is practically irreversible, applications of disease-modifying treatments could be successful only if early diagnosis of AD is available. This review highlights various possibilities for the early diagnosis and therapy of AD and investigates potential adaptation of nanoparticles-dendrimers as a class of well-defined branched polymers that are chemically synthesized with a well-defined shape, size and nanoscopic physicochemical properties reminiscent of the proteins for the treatment of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.